Overall and event-free survival are not important by the use of myeloablative therapy following multiple myeloma: a prospective randomised phase 3 study

Translated title of the contribution: Overall and event-free survival are not important by the use of myeloablative therapy following multiple myeloma: a prospective randomised phase 3 study

C.M. Segeren, P. Sonneveld, B. van der Holt, A.J. Croockewit, G.E.G. Verhoef, J.J. Cornelissen, M.R. Schaafsma, M.H.J. van Oers, P.W. Wijermans, W.E. Fibbe, S. Wittebol, H.C. Schouten, M. van Marwijk Kooy, D.H. Biesma, J.W. Baars, R. Slater, M.C.M. Steijaert, I. Buijt, H.M. Lokhorst

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionOverall and event-free survival are not important by the use of myeloablative therapy following multiple myeloma: a prospective randomised phase 3 study
Original languageUndefined/Unknown
Pages (from-to)2144-2151
Number of pages8
JournalBlood
Volume101
Publication statusPublished - 2003

Cite this